Our Mission

At Nanotrol™ Therapeutics, we are revolutionizing cancer treatment by solving one of the most critical challenges in CAR-T cell therapy: Cytokine Release Syndrome (CRS). Our breakthrough AI-driven platform combines enhanced nanoformulated therapeutics with real-time biomarker optimization to dramatically improve patient outcomes.

We believe that every cancer patient deserves access to the life-saving potential of CAR-T therapy without the fear of severe complications. Through our innovative technology, we're making CAR-T therapy safer, more effective, and accessible to patients worldwide.

Our vision extends beyond just treating CRS – we're building the foundation for next-generation precision medicine that adapts in real-time to each patient's unique biology, setting new standards for therapeutic optimization and patient care.

85% Reduction in Severe CRS Events
10x Enhanced Bioavailability
$200M+ Patent Portfolio Value
24B Market Opportunity by 2030

Leadership Team

World-class expertise in biotechnology, AI, and pharmaceutical development

Dr. Izhar Hasan MD PhD

Dr. Hasan, a primary & urgent care physician, is board certified in family medicine with a subspeciality certification in clinical informatics. He has strong academic interests and has a PhD in medical informatics.

Company Timeline

Key milestones in our journey to revolutionize CRS management

October 2018

Nanotrol™ Therapeutics Founded

Nanotrol™ Therapeutics founded by Dr. Izhar Hasan MD PhD.

October 2020

Nanoformulation development/ via SBIR grant

Completed initial AI algorithm development and Nanotrol™ formulation optimization. Filed first provisional patents for core technology platform.

October 2021

IND filed, Animal PK

IV nanomanufacturing, Oral micronized Salsalate PK study completed/IND submission.

November 2023

USPTO Patent granted

IV nanomanufacturing, Oral micronized Salsalate PK study completed/IND submission.

June 2024

Oral Nanotrol formulated

dissolution study performed.

May 2025

New patent AI

Predictive model/Nanotrol for CRS management